Publicaciones en colaboración con investigadores/as de University of Southern Denmark (28)

2023

  1. Autophagy-mediated control of ribosome homeostasis in oncogene-induced senescence

    Cell Reports, Vol. 42, Núm. 11

  2. Nurses' attitudes towards family importance in nursing care across Europe

    Journal of Clinical Nursing, Vol. 32, Núm. 15-16, pp. 4574-4585

  3. Overall Survival with Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial

    Journal of Clinical Oncology, Vol. 41, Núm. 8, pp. 1590-1599

2022

  1. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

    Blood, Vol. 139, Núm. 6, pp. 835-844

  2. Targeting Signaling Pathway Downstream of RIG-I/MAVS in the CNS Stimulates Production of Endogenous Type I IFN and Suppresses EAE

    International Journal of Molecular Sciences, Vol. 23, Núm. 19

  3. The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies

    Neuro-oncology, Vol. 24, Núm. 9, pp. 1408-1422

2021

  1. A proteomic atlas of lineage and cancer-polarized expression modules in myeloid cells modeling immunosuppressive tumor-infiltrating subsets

    Journal of Personalized Medicine, Vol. 11, Núm. 6

  2. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

    Journal of Clinical Oncology, Vol. 39, Núm. 10, pp. 1139-1149

  3. Genomic and phenotypic insights from an atlas of genetic effects on DNA methylation

    Nature Genetics, Vol. 53, Núm. 9, pp. 1311-1321

  4. Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial

    British Journal of Haematology, Vol. 194, Núm. 1, pp. 132-139

  5. Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)

    Haematologica, Vol. 106, Núm. 6, pp. 1725-1732

  6. The long non-coding RNA MIR31HG regulates the senescence associated secretory phenotype

    Nature Communications, Vol. 12, Núm. 1

2020

  1. Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (Acta Neuropathologica, (2019), 138, 2, (237-250), 10.1007/s00401-019-02026-8)

    Acta Neuropathologica

  2. DNA methylation and body mass index from birth to adolescence: meta-analyses of epigenome-wide association studies

    Genome Medicine, Vol. 12, Núm. 1

  3. Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Obstetrical and Gynecological Survey

2019

  1. Epigenome-wide meta-analysis of DNA methylation and childhood asthma

    Journal of Allergy and Clinical Immunology, Vol. 143, Núm. 6, pp. 2062-2074

  2. Insights on Multiple Myeloma Treatment Strategies

    HemaSphere, Vol. 3, Núm. 1

  3. Niraparib in patients with newly diagnosed advanced ovarian cancer

    New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2391-2402

  4. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

    Blood, Vol. 134, Núm. 8, pp. 668-677

2018

  1. Characterization of Macrophage Endogenous S-Nitrosoproteome Using a Cysteine-Specific Phosphonate Adaptable Tag in Combination with TiO2 Chromatography

    Journal of Proteome Research, Vol. 17, Núm. 3, pp. 1172-1182